PACS Group (PACS) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
29 Nov, 2025Company overview and business model
Operates 276 post-acute care facilities across 15 states, serving over 29,000 patients daily as of September 1, 2024.
Focuses on skilled nursing, senior care, assisted living, and independent living, with a strategy of acquiring underperforming facilities and converting them to high-acuity, short-term transitional care.
Employs a decentralized operating model, empowering local facility leaders and providing centralized support services (PACS Services) for technology, compliance, and back-office functions.
Growth driven by disciplined acquisitions, with a three-year post-acquisition transition period to implement best practices and improve clinical and operational metrics.
Facilities are primarily leased, with ongoing efforts to increase real estate ownership for financial flexibility and value creation.
Financial performance and metrics
For the six months ended June 30, 2024: revenue $1.9B, net income $38.2M, operating expenses $1.8B, Adjusted EBITDA $188.2M.
For the year ended December 31, 2023: revenue $3.1B, net income $112.9M, operating expenses $2.9B, Adjusted EBITDA $237.5M.
Revenue mix for 2023: Medicare 38.6%, Medicaid 37.6%, with the remainder from managed care and private pay.
As of June 30, 2024: total long-term liabilities $2.9B, cash and cash equivalents $73.4M.
Mature facilities (owned >36 months) have a 94% occupancy rate and 4.3 average CMS QM Star rating, both above industry averages.
Use of proceeds and capital allocation
Net proceeds of ~$104.8M from the offering (at $39.67/share) will be used to repay amounts outstanding under the Amended and Restated 2023 Credit Facility.
No proceeds from shares sold by selling stockholders; company has broad discretion in capital allocation.
Latest events from PACS Group
- Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 202527 Feb 2026 - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 20241 Feb 2026 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Shareholders will vote on director elections, auditor ratification, and executive compensation matters.PACS
Proxy Filing25 Nov 2025 - Q3 2024 revenue up 29.8% year-over-year, but net income down amid higher costs and compliance issues.PACS
Q3 202420 Nov 2025 - Q3 2025 revenue up 31% YoY, 2025 guidance raised, but regulatory and financing risks remain.PACS
Q3 202520 Nov 2025 - 2024 revenue up 31% to $4.1B, but net income down 51% amid restatement and higher costs.PACS
Q4 202419 Nov 2025